scholarly journals Serum levels of soluble urokinase plasminogen activator receptor in Japanese patients with chronic kidney disease

2014 ◽  
Vol 86 (1) ◽  
pp. 209-210 ◽  
Author(s):  
Yoshinori Taniguchi ◽  
Yoshiko Shimamura ◽  
Taro Horino ◽  
Shimpei Fujimoto ◽  
Yoshio Terada
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Plasminogen Activator ◽  
Japanese Patients ◽  
Serum Levels ◽  
Urokinase Plasminogen Activator ◽  
Urokinase Plasminogen Activator Receptor ◽  
Plasminogen Activator Receptor

scholarly journals suPAR, a Circulating Kidney Disease Factor

2021 ◽  
Vol 8 ◽  
Author(s):  
Changli Wei ◽  
Ryan Spear ◽  
Eunsil Hahm ◽  
Jochen Reiser
Keyword(s):  
Kidney Disease ◽  
Plasminogen Activator ◽  
Blood Circulation ◽  
Urokinase Plasminogen Activator ◽  
Protein Release ◽  
Urokinase Plasminogen Activator Receptor ◽  
Disease States ◽  
Plasminogen Activator Receptor ◽  
Domain Protein ◽  
Disease Factor

Urokinase plasminogen activator receptor (uPAR) is a multifaceted, GPI-anchored three-domain protein. Release of the receptor results in variable levels of soluble uPAR (suPAR) in the blood circulation. suPAR levels have been linked to many disease states. In this mini-review, we discuss suPAR as a key circulating molecule mediating kidney disease with a particular focus on differently spliced isoforms.

Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Are Elevated in Severe Pre-Eclampsia

2016 ◽  
Vol 5 (4) ◽  
pp. 101-105
Author(s):  
Ville Jalkanen ◽  
Kati Tihtonen ◽  
Kati Jalkanen ◽  
Aaro J. Jalkanen ◽  
Jukka Uotila ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Serum Levels ◽  
Urokinase Plasminogen Activator ◽  
Urokinase Plasminogen Activator Receptor ◽  
Plasminogen Activator Receptor

scholarly journals High baseline soluble urokinase plasminogen activator receptor (suPAR) serum levels indicate adverse outcome after resection of pancreatic adenocarcinoma

2019 ◽  
Vol 40 (8) ◽  
pp. 947-955 ◽  
Author(s):  
Sven H Loosen ◽  
Frank Tacke ◽  
Niklas Püthe ◽  
Marcel Binneboesel ◽  
Georg Wiltberger ◽  
...  
Keyword(s):  
Plasminogen Activator ◽  
Pancreatic Adenocarcinoma ◽  
Tumor Resection ◽  
Serum Levels ◽  
Urokinase Plasminogen Activator ◽  
Healthy Controls ◽  
Urokinase Plasminogen Activator Receptor ◽  
High Baseline ◽  
Plasminogen Activator Receptor

Abstract Surgical resection represents the only potentially curative therapy for patients with pancreatic adenocarcinoma (PDAC), an aggressive malignancy with a very limited 5-year survival rate. However, even after complete tumor resection, many patients are still facing an unfavorable prognosis underlining the need for better preoperative stratification algorithms. Here, we explored the role of the secreted glycoprotein soluble urokinase plasminogen activator receptor (suPAR) as a novel circulating biomarker for patients undergoing resection of PDAC. Serum levels of suPAR were measured by enzyme-linked immunosorbent assay (ELISA) in an exploratory as well as a validation cohort comprising a total of 127 PDAC patients and 75 healthy controls. Correlating with a cytoplasmic immunohistochemical expression of uPAR in PDAC tumor cells, serum levels of suPAR were significantly elevated in PDAC patients compared to healthy controls and patient with PDAC precursor lesions. Importantly, patients with high preoperative suPAR levels above a calculated cutoff value of 5.956 ng/ml showed a significantly reduced overall survival after tumor resection. The prognostic role of suPAR was further corroborated by uni- and multivariate Cox-regression analyses including parameters of systemic inflammation, liver and kidney function as well as clinico-pathological patients’ characteristics. Moreover, high baseline suPAR levels identified those patients particularly susceptible to acute kidney injury and surgical complications after surgery. In conclusion, our data suggest that circulating suPAR represents a novel prognostic marker in PDAC patients undergoing tumor resection that might be a useful addition to existing preoperative stratification algorithms for identifying patients that particularly benefit from extended tumor resection.

scholarly journals Serum Levels of Soluble Urokinase Plasminogen Activator Receptor Predict Tumor Response and Outcome to Immune Checkpoint Inhibitor Therapy

2021 ◽  
Vol 11 ◽  
Author(s):  
Sven H. Loosen ◽  
Joao Gorgulho ◽  
Markus S. Jördens ◽  
Maximilian Schulze-Hagen ◽  
Fabian Beier ◽  
...  
Keyword(s):  
Treatment Response ◽  
Plasminogen Activator ◽  
Immune Checkpoint ◽  
Serum Levels ◽  
Urokinase Plasminogen Activator ◽  
Clinicopathological Parameters ◽  
Individual Treatment ◽  
Healthy Controls ◽  
Urokinase Plasminogen Activator Receptor ◽  
Plasminogen Activator Receptor

BackgroundImmune checkpoint inhibitors (ICIs) have led to a paradigm shift in cancer therapy, improving outcomes in the treatment of various malignancies. However, not all patients benefit to the same extend from ICI. Reliable tools to predict treatment response and outcome are missing. Soluble urokinase plasminogen activator receptor (suPAR) is a marker of immune activation, whose levels are prognostic in various cancers. We evaluated circulating suPAR levels as a novel predictive and prognostic biomarker in patients receiving ICI therapy for solid tumors.MethodsA total of n = 87 patients receiving ICI therapy for different solid malignancies as well as 32 healthy controls were included into this study. Serum levels of suPAR were measured by ELISA prior to and sequentially at two time points during ICI therapy.ResultsBaseline suPAR serum levels were significantly higher in solid tumor patients compared to healthy controls. Importantly, patients with low suPAR levels both before or during ICI treatment were more likely to have a favorable response to treatment at three and six months, respectively. This finding was confirmed by multivariate binary logistic regression analysis including several clinicopathological parameters. Moreover, circulating suPAR levels before and during therapy were an independent prognostic factor for overall survival (OS). As such, patients with initial suPAR levels above our ideal prognostic cut-off value (4.86 ng/ml) had a median OS of only 160 days compared to 705 days for patients with suPAR levels below this cut-off value. Finally, low baseline suPAR levels identified a subgroup of patients who experienced ICI-related side effects which in turn were associated with favorable treatment response and outcome.ConclusionOur data suggest that measurements of suPAR serum levels are a previously unknown, easily accessible tool to predict individual treatment response and outcome to ICI therapy. Circulating suPAR might therefore be implemented into stratification algorithms to identify the ideal candidates for ICI treatment.

Sign in / Sign up

Export Citation Format

Share Document